EGFR and non-small cell lung carcinoma: According to the 2021 NCCN guidelines for non-small cell lung cancer (NSCLC), osimertinib has become the recommended adjuvant therapy for stage Ib-IIIa NSCLC patients with EGFR mutations after surgery [6].